CAR mRNA-LNP-Antibody Conjugate Products

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Background Service What We Can Offer Workflow HighlightsFAQs Contact

Conventional cell therapies face significant hurdles, including complex ex vivo manufacturing, high costs, and persistent safety concerns related to permanent genetic modification. Creative Biolabs' CAR mRNA-LNP-Antibody Conjugate Products offer a transformative solution, an off-the-shelf platform that enables targeted in vivo delivery of CAR mRNA to specific immune cells using antibody-guided lipid nanoparticles. This service provides a fully customizable and scalable pipeline, from target selection to optimized conjugate formulation. The key advantage is the ability to rapidly generate potent, yet transient, CAR-equipped immune cells directly within the patient, thereby accelerating therapeutic development, reducing manufacturing complexity, and enhancing the therapeutic window.

Introduction

CAR mRNA-LNP-Antibody Conjugate technology represents a novel class of therapeutics that combines the precision of antibody targeting with the transient, in vivo expression of chimeric antigen receptors (CARs) via lipid nanoparticle (LNP) delivery. This platform offers a transformative off-the-shelf alternative that overcomes key limitations of conventional cell therapies, including complex ex vivo manufacturing, high costs, and risks associated with permanent genetic modification. By enabling the rapid and specific generation of potent yet transient CAR-equipped immune cells directly within the patient, it holds significant potential to accelerate therapeutic development, improve safety profiles, and broaden the accessibility of advanced immunotherapies for oncology and beyond.

Fig.1 Antibody-guided LNP carriers for in vivo CAR-T cell engineering. (OA Literature) Fig.1 Antibody-conjugated LNP platforms for mRNA-encoded CAR delivery.

CAR mRNA-LNP-Antibody Conjugate Products at Creative Biolabs

Creative Biolabs offers a targeted in vivo T-cell engineering platform that bypasses conventional delivery limitations. By employing antibody ligands with distinct internalization profiles, like CD7 for efficient uptake or CD4 for lineage-specific targeting, the system ensures precise cytosolic delivery of CAR mRNA, enhancing expression while minimizing off-target sequestration and degradation.

What We Can Offer

Our company offers a suite of advanced therapeutic candidates that combine the specificity of monoclonal antibodies with the transient, in vivo CAR expression enabled by mRNA-LNP technology. Each product is designed to selectively deliver CAR-encoding mRNA to specific immune cell subsets via surface receptor targeting, enabling precise and controlled immunomodulation.

Targeted Cytotoxic T Cell Engineering (Anti-CD8 Conjugate): This product delivers CAR mRNA specifically to CD8+ cytotoxic T lymphocytes in vivo to generate a transient population of tumor-redirected effector cells for potent, on-demand anticancer activity.
Modular Helper T Cell Modulation (Anti-CD4 Conjugate): This conjugate directs CAR expression to CD4+ T helper cells, enabling their transient reprogramming to support and enhance antitumor immune responses through cytokine secretion and immune coordination.
Pan-T Cell Redirection Platform (Anti-CD3 Conjugate): By targeting the CD3 complex expressed on all mature T cells, this platform enables broad, transient CAR-T cell generation in vivo for comprehensive antitumor targeting without the need for ex vivo manipulation.
T Cell and B-1 Cell Targeted Therapy (Anti-CD5 Conjugate): This product facilitates CAR mRNA delivery to both T cells and a subset of B cells (B-1 cells), offering a strategic approach for targeting hematological malignancies expressing CD5 or for modulating autoimmune pathways.
Therapeutics for T-ALL and PTCL (Anti-CD7 Conjugate): Engineered to target CD7, this candidate selectively reprograms CD7+ T cells and NK cells in situ, providing a targeted strategy for treating CD7-positive hematologic cancers like T-ALL while potentially mitigating fratricide.
Enhanced T Cell Activation via Co-stimulation (Anti-CD2 Conjugate): This conjugate delivers CAR mRNA to T cells via the CD2 receptor, simultaneously promoting strong T cell activation and proliferation through natural signaling pathways to generate more robust and persistent CAR-T cell responses.

Our Service Process

Required Starting Materials:

Target antigen sequence.
Specific T cell subset.

Key Steps:

Workflow of CAR mRNA-LNP conjugated antibody products at Creative Biolabs. (Creative Biolabs Original)

Final Deliverables:

Fully characterized targeted LNPs.
A comprehensive Batch Analysis Report.

Key Advantages

Bespoke Targeting Ligand Engineering: The integrity and traceability of all biological materials are rigorously verified by certified quality control to ensure superior ligand consistency and binding fidelity.
Internalization-Enhanced LNP Design: We refine CAR codon optimization and lipid composition to enhance mRNA translation efficiency and promote rapid receptor-mediated uptake in defined T-cell populations.
Adaptable Process Optimization: Streamlined upstream mRNA production and downstream LNP processing, with configurable batch, fed-batch, or continuous operational modes to match development timelines.

FAQs

Q1: Why target CD7 instead of high-abundance markers like CD3?

A1: Surface abundance does not guarantee efficient delivery. CD3, while highly expressed, internalizes slowly. In contrast, CD7 undergoes rapid, constitutive endocytosis, functioning as a precise molecular shuttle that facilitates swift and effective LNP entry into the cytosol. This kinetic advantage minimizes off-target sequestration and maximizes functional mRNA delivery before potential degradation.

Q2: What is the risk of systemic immunogenicity with targeted LNPs?

A2: Immunogenicity is rigorously mitigated through a multi-pronged strategy. Our platform employs proprietary, ionizable lipids engineered for low reactogenicity, combined with highly purified, nucleoside-modified mRNA that evades innate immune sensing. This integrated design specifically dampens unwanted TLR7/8 activation in endosomes, thereby establishing a favorable safety profile with substantially reduced systemic inflammation compared to conventional lipid-based systems.

Why Choose Us?

Our CAR mRNA-LNP platform is distinguished by a targeted ligand-optimization strategy, prioritizing rapid cellular internalization over conventional receptor binding. CD7-directed formulations demonstrate exceptional uptake kinetics, ensuring efficient cytosolic mRNA delivery. This specificity is further augmented by custom-engineered lipids that actively promote extrahepatic biodistribution to immune cell-rich compartments. Consequently, our platform achieves robust and reproducible therapeutic outcomes, with published studies confirming high levels of in vivo target cell modification and corresponding functional potency.

Customer Reviews

"Creative Biolabs' CD7-targeted CAR mRNA-LNP antibody conjugate allowed our team to achieve precise T-cell transfection with minimal hepatic sequestration, a key limitation of conventional LNP delivery systems."

— Dr. J*s L.

"Their CD7-directed platform enabled a critical transition from in vitro validation to in vivo therapeutic efficacy, where rapid receptor-mediated internalization ensured robust CAR expression at suboptimal dosing levels."

— Prof. S*n K.

"Implementation of this platform has provided exceptional manufacturing reproducibility and comprehensive analytical validation, meeting the stringent consistency requirements essential for our regulatory submission pathway."

— Dr. E*a R.

How to contact us?

Creative Biolabs pioneers the development of next-generation CAR mRNA-LNP conjugates, integrating precision receptor kinetics with scalable production to enable highly efficient in vivo cellular reprogramming. Our proprietary, kinetics-optimized platform, validated in peer-reviewed research, delivers enhanced safety profiles, reduced development costs, and significantly accelerated translational timelines.

To explore a tailored collaboration or request a detailed technical consultation.